← Leaderboards
Shihui Liu
University Of Pittsburgh At Pittsburgh
$7,676,261
Attributed
$7,676,261
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,676,261 · 5
By mechanism
R01$7,158,739 · 4
R56$517,522 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Bruce A Mc Clane$13,048,720
- Jill M Siegfried$10,296,579
- Pamela A Hershberger$2,530,355
- Julian Rood$693,763
- Francisco A Uzal$1,415,271
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsIn VivoToxinTissuesMolecularTargeted TreatmentPathogenesisTargeted ToxinsBindingPathogenic BacteriaProteinsMeksLinkAnthrax Lethal FactorToxic EffectCell TypePathway InteractionsReceptorCell ProliferationMap Kinase GeneExpectationMouse ModelPathogenComplement
Grant awards (15)
Highly tumor-selective pan RAS inactivators for targeting oncogenic RAS-driven cancers$657,776
R01 · FY2025 · CA · contact PI
Mechanisms of anthrax lethal toxin-induced mortality and the novel biological-based targeted therapies$592,728
R01 · FY2025 · AI · contact PI
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment$452,287
R01 · FY2025 · CA · contact PI
Mechanisms of anthrax lethal toxin-induced mortality and the novel biological-based targeted therapies$611,060
R01 · FY2024 · AI · contact PI
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies$501,667
R01 · FY2024 · AI · contact PI
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment$425,913
R01 · FY2024 · CA · contact PI
Mechanisms of anthrax lethal toxin-induced mortality and the novel biological-based targeted therapies$606,290
R01 · FY2023 · AI · contact PI
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies$504,847
R01 · FY2023 · AI · contact PI
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment$443,241
R01 · FY2023 · CA · contact PI
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies$506,279
R01 · FY2022 · AI · contact PI
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment$436,990
R01 · FY2022 · CA · contact PI
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies$501,604
R01 · FY2021 · AI · contact PI
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartment$428,973
R01 · FY2021 · CA · contact PI
Molecular mechanisms and novel biological-based therapies for anthrax lethal toxin-induced mortality$517,522
R56 · FY2020 · AI · contact PI
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies$489,084
R01 · FY2020 · AI · contact PI